Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Start-ups

Rivus launches with $35 million to tackle obesity, metabolic diseases

by Megha Satyanarayana
July 23, 2021 | A version of this story appeared in Volume 99, Issue 27

 

Rivus Pharmaceuticals is launching with $35 million in series A financing to develop its small molecule HU6 into a treatment for metabolic and cardiovascular diseases. HU6 is a controlled metabolic accelerator, a class of compounds that spur the breakdown of fats and sugars. HU6 is in phase 2 clinical trials to establish safety and efficacy in people with high body mass indices who have evidence of fatty liver. The funding is led by Longitude Capital and Medicxi.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.